Fingerprint
Dive into the research topics of 'A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors
Maxime Chénard-Poirier, Aaron R. Hansen, Martin E. Gutierrez, Drew Rasco, Yan Xing, Lin Chi Chen, Heng Zhou, Andrea L. Webber, Tomoko Freshwater, Manish R. Sharma
Research output: Contribution to journal › Article › peer-review